Alnylam Pharmaceuticals (ALNY) – Investment Analysts’ Recent Ratings Updates

Several brokerages have updated their recommendations and price targets on shares of Alnylam Pharmaceuticals (NASDAQ: ALNY) in the last few weeks:

• 11/2/2026 – Alnylam Pharmaceuticals had its price target lowered by Barclays from $450.00 to $380.00. They now have an “overweight” rating on the stock.
• 11/2/2026 – Alnylam Pharmaceuticals had its price target lowered by Canaccord Genuity Group from $429.00 to $323.00. They now have a “buy” rating on the stock.
• 11/2/2026 – Alnylam Pharmaceuticals was downgraded by Truist Financial from “buy” to “hold”. They now have a $225.00 price target on the stock, down from $315.00.
• 10/30/2026 – Alnylam Pharmaceuticals had its price target lowered by UBS Group from $550.00 to $329.00. They now have a “buy” rating on the stock.
• 10/30/2026 – Alnylam Pharmaceuticals had its “outperform” rating reaffirmed by BMO Capital Markets. They now have a $290.00 price target on the stock.
• 10/30/2026 – Alnylam Pharmaceuticals had its “buy” rating reaffirmed by Bank of America. They now have a $287.00 price target on the stock, down from $460.00.
• 10/30/2026 – Alnylam Pharmaceuticals was downgraded by Raymond James Financial from “strong-buy” to “outperform”. They now have a $315.00 price target on the stock, down from $420.00.
• 10/30/2026 – Alnylam Pharmaceuticals had its price target lowered by Chardan Capital from $425.00 to $375.00. They now have a “buy” rating on the stock.
• 10/30/2026 – Alnylam Pharmaceuticals had its price target lowered by Oppenheimer from $350.00 to $320.00. They now have an “outperform” rating on the stock.
• 10/30/2026 – Alnylam Pharmaceuticals had its price target lowered by TD Cowen from $482.00 to $354.00. They now have a “buy” rating on the stock.
• 10/30/2026 – Alnylam Pharmaceuticals had its price target lowered by Morgan Stanley from $300.00 to $240.00. They now have an “equal weight” rating on the stock.
• 10/30/2026 – Alnylam Pharmaceuticals had its price target lowered by The Goldman Sachs Group from $536.00 to $320.00. They now have a “buy” rating on the stock.
• 10/30/2026 – Alnylam Pharmaceuticals had its price target lowered by Wells Fargo & Company from $253.00 to $220.00. They now have an “equal weight” rating on the stock.
• 10/30/2026 – Alnylam Pharmaceuticals had its price target lowered by Royal Bank Of Canada from $345.00 to $280.00. They now have an “outperform” rating on the stock.
• 10/30/2026 – Alnylam Pharmaceuticals was downgraded by Sanford C. Bernstein from “outperform” to “market perform”. They now have a $199.00 price target on the stock, down from $376.00.
• 10/29/2026 – Alnylam Pharmaceuticals had its “hold (c)” rating reaffirmed by Weiss Ratings.
• 10/29/2026 – Alnylam Pharmaceuticals had its price target lowered by Needham & Company LLC from $357.00 to $243.00. They now have a “buy” rating on the stock.
• 10/29/2026 – Alnylam Pharmaceuticals was downgraded by Stifel Nicolaus from “buy” to “hold”. They now have a $225.00 price target on the stock.
• 10/28/2026 – Alnylam Pharmaceuticals had its “buy” rating reaffirmed by HC Wainwright.
• 10/23/2026 – Alnylam Pharmaceuticals was downgraded by Zacks Research from “strong-buy” to “hold”.
• 10/15/2026 – Alnylam Pharmaceuticals is now covered by UBS Group. They set a “buy” rating and a $354.00 price target on the stock.
• 10/14/2026 – Alnylam Pharmaceuticals was upgraded by UBS Group to “strong-buy”.
• 10/14/2026 – Alnylam Pharmaceuticals had its price target lowered by Citigroup from $340.00 to $320.00. They now have a “buy” rating on the stock.
• 10/14/2026 – Alnylam Pharmaceuticals had its price target lowered by Wells Fargo & Company from $256.00 to $253.00. They now have an “equal weight” rating on the stock.
• 10/9/2026 – Alnylam Pharmaceuticals had its price target lowered by Bank of America from $346.00 to $336.00.
• 10/8/2026 – Alnylam Pharmaceuticals had its price target lowered by Royal Bank Of Canada from $350.00 to $345.00. They now have an “outperform” rating on the stock.
• 10/5/2026 – Alnylam Pharmaceuticals was upgraded by Zacks Research from “hold” to “strong-buy”.
• 9/30/2026 – Alnylam Pharmaceuticals had its “neutral” rating reaffirmed by Cantor Fitzgerald.
• 9/30/2026 – Alnylam Pharmaceuticals had its price target lowered by JPMorgan Chase & Co. from $375.00 to $369.00. They now have an “overweight” rating on the stock.
• 9/21/2026 – Alnylam Pharmaceuticals had its “buy” rating reaffirmed by HC Wainwright. They now have a $455.00 price target on the stock.

Alnylam Pharmaceuticals Stock Down 0.4%

Alnylam Pharmaceuticals stock traded down $0.61 during midday trading on Thursday, hitting $159.24. 974,470 shares of the company were exchanged, compared to its average volume of 1,586,290. The company has a market cap of $21.33 billion, a PE ratio of 8.27 and a beta of 0.42. Alnylam Pharmaceuticals, Inc. has a fifty-two week low of $149.18 and a fifty-two week high of $479.79. The company’s fifty day moving average price is $223.45 and its 200-day moving average price is $277.97. The company has a debt-to-equity ratio of 0.18, a current ratio of 2.48 and a quick ratio of 2.43.

Alnylam Pharmaceuticals (NASDAQ:ALNY) last issued its quarterly earnings data on Thursday, October 29th. The biopharmaceutical company reported $16.26 earnings per share (EPS) for the quarter, beating the consensus estimate of $1.66 by $14.60. Alnylam Pharmaceuticals had a net margin of 52.85% and a return on equity of 155.33%. The company had revenue of $1.46 billion during the quarter, compared to the consensus estimate of $1.43 billion. During the same quarter last year, the company earned $2.90 earnings per share. Alnylam Pharmaceuticals’s revenue for the quarter was up 16.7% on a year-over-year basis. On average, research analysts predict that Alnylam Pharmaceuticals, Inc. will post 6.85 EPS for the current fiscal year.

Insiders Place Their Bets

In related news, EVP Bryan Supran sold 1,758 shares of the firm’s stock in a transaction on Friday, October 2nd. The shares were sold at an average price of $226.88, for a total transaction of $398,855.04. Following the completion of the sale, the executive vice president directly owned 12,807 shares of the company’s stock, valued at approximately $2,905,652.16. This trade represents a 12.07% decrease in their position. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through this link. The sale was made to cover tax withholding obligations related to the vesting of equity awards. Insiders own 0.86% of the company’s stock.

Alnylam Pharmaceuticals is a biopharmaceutical company focused on discovering, developing and commercializing medicines based on RNA interference (RNAi), a biological process that can reduce the production of specific disease-causing proteins. Founded in 2002 and headquartered in Cambridge, Massachusetts, the company helped advance RNAi from a scientific discovery into a therapeutic approach. Its marketed medicines include ONPATTRO (patisiran) and AMVUTTRA (vutrisiran) for hereditary transthyretin-mediated amyloidosis, GIVLAARI (givosiran) for acute hepatic porphyria, and OXLUMO (lumasiran) for primary hyperoxaluria type 1.